Canaccord raised the firm’s price target on Vertex Pharmaceuticals to $315 from $312 and keeps a Hold rating on the shares. The firm said they once again delivered a top- and bottom-line beat, driven largely by continued commercial execution with Trikafta/Kaftrio. On that note, the company also raised CF product revenue guidance to $9.7-9.8B. On the pipeline front, key milestones across several programs are on track setting up a fairly busy 2H23.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on VRTX:
- Vertex: VX-548 preclinical studies, Phase 2, proof-of-concept results published
- Vertex Pharmaceuticals price target raised to $425 from $410 at Wells Fargo
- Vertex Pharmaceuticals price target raised to $370 from $360 at TD Cowen
- Vertex Pharmaceuticals price target raised to $390 from $380 at Bernstein
- Vertex Pharmaceuticals price target raised to $399 from $384 at Barclays
Questions or Comments about the article? Write to editor@tipranks.com